Bayer and Atara to collaborate on CAR-T cell therapies
Under the terms of the agreement, Atara will lead IND (Investigational New Drug) enabling studies and process development for ATA3271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization






























